ReviewHistopathology2019
Grading of prostate cancer: a work in progress.
Review in Histopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.ESMO open · 2022Guideline
- An X-ray micro-CT protocol enables non-destructive 3D visualization of glandular architecture in archived paraffin-embedded prostate cancer tissue.The journal of pathology. Clinical research · 2026Article
- Reply to Dr. Zhang's Letter to the Editor re: R.M. Bernardino, L.B. Yin, K. Lajkosz, et al. Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial. Eur Urol Open Sci 2025;82:52-8.European urology open science · 2026Article
- A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer.Discover oncology · 2026Article
- Article
- Review
- The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.Virchows Archiv : an international journal of pathology · 2026Review
- Validation of a Renal Papillary Grading System: Comparison of Patients Forming Calcium Oxalate and Apatite Stones.Journal of endourology · 2026Article
- Artificial intelligence in prostate biopsy: diagnostic applications, risk stratification, and precision oncology.Frontiers in oncology · 2026Review
- A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors.Journal of translational medicine · 2025Article
- EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study.Cancers · 2025Article
- Review
- Does grade matter? Evaluation of histologic grade in patients with stage 1 non-small cell lung cancer using the National Cancer Database.JTCVS open · 2025Article
- Impact of Cribriform Pattern on Progression-Free Survival After Radical Prostatectomy in Gleason Score 8-10 Prostate Cancer.The Eurasian journal of medicine · 2025Article
- Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.Asian journal of andrology · 2024Review
- Multinational, Multicenter Evaluation of Prostate Cancer Tissue in Sub-Saharan Africa: Challenges and Opportunities.JCO global oncology · 2024Article
- Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era.Urologic oncology · 2024Article
- Review
- The Current Therapeutic Landscape for Metastatic Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?The Prostate · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Grading of prostate cancer has evolved substantially over time, not least because of major changes in diagnostic approach and concomitant shifts from late- to early-stage detection since the adoption of PSA testing from the late 1980s. After the conception of the architecture-based nine-tier Gleason grading system more than 50 years ago, several changes were made in order to increase its prognostic impact, to reduce interobserver variation and to improve concordance between prostate needle biopsy and radical prostatectomy grading. This eventually resulted in the current five-tier grading system, with a much more detailed description of the individual architectural patterns constituting the remaining three Gleason patterns (i.e. grades 3-5). Nevertheless, there is room for improvement. For instance, distinction of common grade 4 subpatterns such as ill-formed and fused glands from the grade 3 pattern is challenging, blurring the division between low-risk patients who could be eligible for deferred therapy and those who need curative therapy. The last few years have witnessed the publication of several studies on the prognostic impact of individual architectural subpatterns showing that, in particular, the cribriform pattern exceeded the prognostic impact of other grade 4 subpatterns. This review provides an overview of the changes in prostate cancer grading over time and provides a thorough description of the various Gleason subpatterns, the current evidence of their prognostic impact and areas of contention. Potential practical ways for improvements of the current grading system are also put forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.